COVID-19 Pneumonia After SARS-CoV-2 Vaccination with CoronaVac: A Case Series from Turkey

Abstract

Coronavirus disease 2019 is a novel viral infection that has caused a pandemic globally. Many kinds of vaccine development studies were conducted to prevent the spread and deaths. The CoronaVac is the most commonly used vaccine in Turkey. Phase 3 trials from various countries revealed that CoronaVac efficacy ranged from 50.7% to 91.25% but increased in moderate or severe cases to 100%. Additionally, it was remarkable owing to high seroconversion rates achieving up to 100%. After the vaccine campaign began in Turkey, critically ill patients continued to admit to our center's intensive care unit though they had been vaccinated with 2 doses of CoronaVac. The clinical course of these patients revealed that they are still at high risk of severe disease and death. Therefore, we aimed to share these patients' clinical characteristics and disease course, laboratory, and radiologic data.

Figure 1.

Axial thorax computed tomography findings of the patients are shown in (A-F). (A) Multiple subpleural consolidations and ground-glass opacities, (B) widespread ground-glass opacities and consolidations, (C) ground-glass opacities and reticular densities, (D) subpleural multicentric ground glass opacities prominently in left the lung and diffuse emphysema in both lungs, (E) widespread ground-glass opacities and consolidations in both lungs, and (F) ground-glass opacities and reticular densities prominently in the left lung. CT, computed tomography.